Skip to main content

Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity

Psychopharmacology volume 173, pages 234–241 (2004)Cite this article

Abstract

Aims

Not every tablet sold as “ecstasy” contains MDMA (3,4-methylenedioxymethamphetamine). The historical origins and evolution of this mismatch will be reviewed, in order to estimate the proportions of ecstasy tablets containing MDMA at different periods over the past 30 years.

Methods

Surveys into the pharmacological constituents of ecstasy tablets, dosage levels, and empirical reports of their perceived purity, provide the main data for this review.

Results

During the 1980s and early 1990s there were few problems with the purity of ecstasy tablets, and the biochemical evidence shows that they nearly always contained MDMA. During the mid-1990s, the majority of ecstasy tablets continued to contain MDMA, while many others comprised MDA (3,4-methylenedioxyamphetamine), MDEA (3,4-methylenedioxyethylamphetamine), or amphetamine drug mixtures. However, a small proportion (4–20% according to survey, time and place), comprised non-amphetamine drugs such as caffeine, ephedrine, ketamine, paracetamol, or placebo. During the late 1990s, the proportion of ecstasy tablets containing MDMA increased to around 80–90%. The latest reports suggest that non-MDMA tablets are now very infrequent, with purity levels between 90% and 100%. Dosage levels of tablets are also highly variable, with low dose tablet often encountered during the mid-1990s, and high dose tablets now seen more frequently. The theoretical and practical implications of these findings will be debated.

Conclusions

The ecstasy purity problem was predominantly a phenomenon of the mid to late 1990s, when many tablets contained substances other than MDMA. Before and since then, the proportion of ecstasy tablets containing MDMA has been very high.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References

  • Baggott M, Heifets B, Jones RT, Mendelson J, Sferios E, Zehnder J (2000) Chemical analysis of ecstasy pills. JAMA 284:2190

    CAS  PubMed  Google Scholar 

  • Beck J (1990) The public health implications of MDMA use. In: Peroutka SJ (ed) Ecstasy: the clinical pharmacology and neurotoxicological effects of MDMA. Kluwer, Boston

  • Berger UV, Gu XF, Azmitia EC (1992) The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, para-chloroamphetamine and fenfluramine induce 5-hydroxytrypamine release via a common mechanism blocked by fluoxetine and cocaine. Eur J Pharmacol 215:153–160

    CAS  PubMed  Google Scholar 

  • Cohen RS (1998) The love drug: marching to the beat of ecstasy. Haworth Medical Press, New York State

    Google Scholar 

  • Cole JC, Bailey M, Sumnall HR, Wagstaff GF, King LA (2002) The contents of ecstasy tablets: implications for the study of their long-term effects. Addiction 97:1531–1536

    Article  PubMed  Google Scholar 

  • Cuomo MJ, Dyment PG, Gammino VM (1990) Increasing use of “ecstasy” (MDMA) and other hallucinogens on a college campus. J Am Coll Health 42:271–274

    Google Scholar 

  • Curran V (2000) Is MDMA (“ecstasy”) neurotoxic in humans? An overview of evidence and methodological problems in research. Neuropsychobiology 42:34–41

    CAS  PubMed  Google Scholar 

  • Davison D, Parrott AC (1997) Ecstasy in recreational users: self-reported psychological and physiological effects. Hum Psychopharmacol 12:91–97

    Article  Google Scholar 

  • Dowling GP (1990) Human deaths and toxic reactions attributed to MDMA and MDEA. In: Peroutka SJ (ed) Ecstasy: the clinical pharmacology and neurotoxicological effects of MDMA. Kluwer, Boston

  • Dye C (1982a) MDA/MDM: the chemical pursuit of ecstasy. Do it Now Publications, Phoenix, Ariz.

  • Dye C (1982b) XTC: the chemical pursuit of pleasure. Drug Survival News 10:8–9

    Google Scholar 

  • Fischer HS, Zernig G, Schatz DS, Humpel C, Saria A, (2000) MDMA (“ecstasy”) enhances basal acetylcholine release in brain slices of the rat striatum. Eur J Neurosci 12:1385–1390

    Article  CAS  PubMed  Google Scholar 

  • Fox H, Parrott AC, Turner JJD (2001) Ecstasy/MDMA related cognitive deficits: a function of dosage rather than awareness of problems. J Psychopharmacol 15:273–281

    CAS  PubMed  Google Scholar 

  • Fox HC, McLean A, Turner JJD, Parrott AC, Rogers R, Sahakian BJ (2002) Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA (“ecstasy”) polydrug users. Psychopharmacology 162:203–214

    Article  CAS  PubMed  Google Scholar 

  • Green AR, Cross AJ, Goodwin GM (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy). Psychopharmacology 119:247–260

    CAS  PubMed  Google Scholar 

  • Green AR, Mechan AO, Elliott JM, O’Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev (in press)

  • Hammersley R, Ditton J, Smith I, Short E (1999) Patterns of ecstasy use by drug users. Br J Criminol 39:625–647

    Article  Google Scholar 

  • Handy C, Pates R, Barrowcliff A (1998) Drug use in South Wales: who uses ecstasy anyway? J Subst Misuse 3:82–88

    Google Scholar 

  • Hansen D, Maycock B, Lower T (2001) “Weddings, parties, anything...”, a qualitative analysis of ecstasy use in Perth, Western Australia. Int J Drug Policy 12:181–199

    Article  PubMed  Google Scholar 

  • Hegadoren KM, Baker GB, Bourin M (1999) 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev 23:539–553

    CAS  PubMed  Google Scholar 

  • Henry JA, Jeffries KJ, Dawling S (1992). Toxicity and deaths from 3,4-methylenedioxymethamphetamine (“ecstasy”). Lancet 340:384–387

    CAS  PubMed  Google Scholar 

  • Jackson B, Reed A (1970) Another abusable amphetamine. JAMA 211:830

    Article  CAS  Google Scholar 

  • King LA (2000) Was it MDMA? Neuropsychobiology 42:45–46

    Google Scholar 

  • McCann UD, Eligulashvili V, Ricaurte GA (2000) (±) 3,4-methylenedioxymethamphetamine (“ecstasy”)-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 42:11–16

    CAS  Google Scholar 

  • McDowell DM, Kleber HD (1994) MDMA: its history and Pharmacology. Psychiatr Ann 24:127–130

    Google Scholar 

  • Milroy CM, Clark JC, Forrest ARW (1996) Pathology of deaths associated with “ecstasy” and “eve”. J Clin Pathol 49:149–153

    CAS  PubMed  Google Scholar 

  • Morgan MJ (2000) Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology 152:230–248

    CAS  PubMed  Google Scholar 

  • Palenicek T, Fiserova M, Kubu P (2002) Test of ecstasy tablets in Czech Republic—quantitative analysis. Adiktologie 1:70–71

    Google Scholar 

  • Parrott AC (2000) Human research on MDMA (3,4-methylenedioxymethamphetamine) neurotoxicity: cognitive and behavioral indices of change. Neuropsychobiology 42:17–24

    CAS  PubMed  Google Scholar 

  • Parrott AC (2001) Human psychopharmacology of ecstasy/MDMA: a review of fifteen years of empirical research. Hum Psychopharmacol 16:557–578

    CAS  Google Scholar 

  • Parrott AC (2002a) Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 71:837–844

    Article  CAS  Google Scholar 

  • Parrott (2002b) Tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or ecstasy. Psychobiol Newsletter (Winter):16–17

    Google Scholar 

  • Parrott AC, Sisk E, Turner J (2000) Psychobiological problems in heavy “ecstasy” (MDMA) polydrug users. Drug Alcohol Depend 60:105–110

    CAS  PubMed  Google Scholar 

  • Parrott AC, Milani R, Parmar R, Turner JJD (2001) Ecstasy polydrug users and other recreational drug users in Britain and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 159:77–82

    CAS  PubMed  Google Scholar 

  • Parrott AC, Fox HC, Milani RM, Soar K, Turner JJD (2002) Polydrug use amongst recreational ecstasy users. Adiktologie 1:71

    Google Scholar 

  • Pedersen W, Skrondal A (1999) Ecstasy and new patterns of drug use: a normal population study. Addiction 94:1695–1706

    Article  CAS  PubMed  Google Scholar 

  • Peroutka SJ (1989) “Ecstasy”: a human neurotoxin? Arch Gen Psychiatry 46:191

    CAS  Google Scholar 

  • Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1:273–277

    CAS  PubMed  Google Scholar 

  • Polkis A, Mackell MA, Drake WK (1979) Fatal intoxication from 3,4-methylenedioxyamphetamine. J Forens Sci 24:70–75

    Google Scholar 

  • Pope HG, Ionescu-Pioggia M, Pope KW (2001) Drug use and lifestyle among college undergraduates: a 30 year longitudinal study. Am J Psychiatry 158:1519–1520

    Article  PubMed  Google Scholar 

  • Ramsey JD (2003) Personal Communication

  • Ramsey JD, Butcher MA, Murphy MF, Lee T, Johnson A, Holt DW (2001) A new method to monitor drugs at dance venues. BMJ 232:603

    Google Scholar 

  • Renfroe CL (1986) MDMA on the street: analysis anonymous. J Psychoact Drugs 18:363–369

    CAS  Google Scholar 

  • Riley SCE, James C, Gregory D, Dingle H, Cadger M (2001) Patterns of recreational drug use at dance events in Edinburgh, Scotland. Addiction 96:1035–1047

    Article  CAS  PubMed  Google Scholar 

  • Rodgers J (2000) Cognitive performance amongst recreational users of “ecstasy”. Psychopharmacology 151:19–24

    CAS  PubMed  Google Scholar 

  • Saunders N (1995) Ecstasy and the dance culture. Neal’s Yard Desktop Publishing, London

  • Schifano F (2000) Potential human neurotoxicity of MDMA (“ecstasy”): subjective self-reports, evidence form an Italian drug addiction centre and clinical case studies. Neuropsychobiology 42:25–33

    CAS  PubMed  Google Scholar 

  • Schifano F, Oyefeso A, Webb L, Pollard M, Corkery J, Ghodse AH (2003) Review of deaths related to taking ecstasy, England and Wales, 1997–2000. BMJ 326:8–81

    Article  PubMed  Google Scholar 

  • Scholey AB, Parrott AC, Buchanan T, Heffernan T, Ling J, Rodgers J (2004) Increased intensity of ecstasy and polydrug usage in the more experienced recreational ecstasy/MDMA users: a www study. Addict Behav (in press)

  • Sherlock K, Wolff K, Hay AWM, Conner M (1999) Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. J Accident Emerg Med 16:194–197

    CAS  Google Scholar 

  • Shulgin AT, Nichols DE (1978) Characteristics of three new psychotomimetics. In: Stillman RC, Willette RE (eds) The pharmacology of hallucinogens. Pergamon, New York

  • Solowij N (1993) Ecstasy (3,4-methylenedioxymethamphetamine). Curr Opin Psychiatry 6:411–415

    Google Scholar 

  • Solowij N, Hall W, Lee N (1992) Recreational MDMA use in Sydney: a profile of ecstasy users and their experiences with the drug. Br J Addict 87:1161–1172

    CAS  PubMed  Google Scholar 

  • Spruit IP (2001) Monitoring synthetic drug markets, trends and public health. Subst Use Misuse 36:23–47

    Article  CAS  PubMed  Google Scholar 

  • Steele TD, McCann UD, Ricaurte GA (1994) 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”): pharmacology and toxicology in animals and humans. Addiction 89:539–551

    CAS  PubMed  Google Scholar 

  • Topp L, Hando J, Dillon P, Roche A, Solowij N (1999) Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 55:105–115

    CAS  PubMed  Google Scholar 

  • Wijngaart van de GM, Braam R, de Bruin D, Fris M, Maalste NJM, Verbraeck HT (1999) Ecstasy use at large scale dance events in the Netherlands. J Drug Issues 29:679–702

    Google Scholar 

  • Winstock AR, Griffiths P, Stewart D (2001) Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 64:9–17

    Article  CAS  PubMed  Google Scholar 

  • World Health Organization (1996) Amphetamine like stimulants. Report from the WHO meeting on amphetamines, MDMA and other psychostimulants. November 1996. WHO, Geneva, Switzerland

Download references

Author information

Authors and Affiliations

  1. Department of Psychology, University of Wales Swansea, Swansea , SAZ 8PP, Uited Kingdom

    A. C. Parrott

Authors
  1. A. C. Parrott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. C. Parrott.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Parrott, A.C. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology 173, 234–241 (2004). https://doi.org/10.1007/s00213-003-1712-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-003-1712-7

Keywords

  • MDMA
  • Ecstasy
  • Amphetamine
  • Stimulant
  • Serotonin
  • MDMA tablet purity
  • MDMA tablet analysis